HZNPinactive

Horizon Therapeutics Public Ltd Co

Healthcare·Oncology·Commercial

OncologyImmunologyOphthalmologyMetabolicPainDermatologyNephrologyMusculoskeletalEndocrinology

Horizon Therapeutics Public Ltd Co (HZNP): 14 pipeline candidates · ~15 mo cash runway · 4 clinical trials. Updated within the last hour.

8.5/10

BioSniper Score

4-factor signal · derived from public data

Cash Runway4.2

15.0 months

Financial Health9.6

2% dilution

Pipeline Maturity10.0

Lead: Approved

Pipeline Breadth10.0

14 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for Horizon Therapeutics Public Ltd Coacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

—

Cash

$2.5B

Quarterly Burn

$582.2M

Runway

15.0 mo

Revenue

$945.0M

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Sep 2027

Today~17 mo out

Catalyst within runway

Pipeline (14 candidates)

Drug	Phase	Indication
antibody-drug conjugate	Phase 1/Phase 2	Cancer
camoteskimab	Phase 2	Atopic Dermatitis
duexis	Approved	—
htx-011	Phase 3	Analgesia
krystexxa	Approved	Uncontrolled gout
pennsaid	Approved	—
procysbi	Approved	nephropathic cystinosis
ptp-01	Phase 3	Knee Osteoarthritis
ravicti	Approved	urea cycle disorders
rayos	Approved	—

Showing 10 of 14 candidates. Sign up for full pipeline.

4 clinical trials·CEO: Transaction Agreement

Frequently asked questions

How many drug candidates are in Horizon Therapeutics Public Ltd Co's pipeline?

Horizon Therapeutics Public Ltd Co (HZNP) has 14 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is Horizon Therapeutics Public Ltd Co's lead drug candidate?

Horizon Therapeutics Public Ltd Co's most advanced tracked candidate is antibody-drug conjugate (Phase 1/Phase 2) for Cancer.

What is Horizon Therapeutics Public Ltd Co's cash runway?

Based on its most recent reported cash balance and quarterly burn rate, Horizon Therapeutics Public Ltd Co has approximately 15.0 months of cash runway.

Who is the CEO of Horizon Therapeutics Public Ltd Co?

Transaction Agreement is the chief executive officer of Horizon Therapeutics Public Ltd Co (HZNP).

Get the full picture on Horizon Therapeutics Public Ltd Co

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free Analysis Browse Calendar